HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an enrollment update with 60% of the target number of subjects for the ...
CEO Walter Klemp highlighted the official start of the Phase 3 MIRACLE trial for Annamycin, with the first patient treated and a total of 38 sites now selected worldwide. He noted, "We just announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback